
    
      This was a phase 3, multicenter, randomized, open-label, active-controlled study. The study
      was planned to provide key efficacy and safety data for the approval of roxadustat in the
      treatment of anemia associated with CKD. Participants assigned to roxadustat treatment were
      administered roxadustat orally as a combination of tablets of different strengths.
      Participants assigned to darbepoetin alfa treatment were administered darbepoetin alfa
      subcutaneously or intravenously.

      The study consisted of 3 study periods:

        -  Screening period: up to 6 weeks

        -  Treatment period: 104 weeks

        -  Follow-up period: 4 weeks until planned study end (end of year 2)
    
  